secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001600620-24-000089
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q2 net product revenue $55M (+34% YoY); net income $0.7M, cash flow positive
--------------------------------------------------------------------------------

- Net product revenue $55.0M, up 34% YoY; total net revenue $57.2M (+38% YoY).
- Net income $0.7M vs loss of $11.5M in Q2 2023; generated $15.8M free cash flow.
- Narrows 2024 net product revenue guidance to $210-220M from $200-220M.
- 2,336 patients on LUPKYNIS (+22% YoY); AUR200 Phase 1 SAD starts Q3 2024.
- Cash $330.7M; repurchased 3.4M shares for $18.6M YTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000089/0001600620-24-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000089/auph-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer